Is there a role for VeriStrat testing in determining when to use an EGFR TKI in previously treated squamous cell NSCLC?

Excellent question and one that we have very little data to answer. Extrapolating from the second line PROSE trial (http://www.ncbi.nlm.nih.gov/pubmed/24831979), it seems reasonable to consider this test to help choose between TKI vs. chemotherapy as a third line option. That said, there are certain...